Insights from 2024 WCLC


 

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimertinib in 1L EGFR-Mut Advanced NSCLC

252 views
September 20, 2024
Comments 0
Login to view comments. Click here to Login